

Technology Transfer in Biotechnology

A Global Perspective

Edited by

Prabuddha Ganguli, Rita Khanna, and Ben Prickril



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Contents

List of Contributors XI

- 1 Defining the Future: Emerging Issues in Biotechnology, Intellectual Property Rights and Technology Transfer 1**
Prabuddha Ganguli, Ben Prickril, and Rita Khanna
- 1.1 Introduction 1
- 1.2 Historical Evolution of Intellectual Property Regime in Biotechnology 1
- 1.3 Issue of Patentability of Gene Sequences, Antibodies, Early-Stage Technology/Platform and 'Insufficient Support for Claims' 2
- 1.4 Scope of Patent Claims 4
- 1.5 Institutional Arrangements for Technology Transfer 7
- 1.6 Policy Issues and Challenges 8
- Part I Technology Transfer Policy Considerations and Country/Regional 13**
- 2 Technology Transfers in Europe within the Life Sciences 15**
Jacques Warcoin
- 2.1 Biology and the Development of Technology Transfers 15
- 2.2 Involvement of Public Bodies 16
- 2.3 Initial Contacts 17
- 2.4 Non-Disclosure Agreements 17
- 2.5 Preliminaries to Negotiations for a Technical Transfer Agreement 20
- 2.6 Memorandum of Understanding or Letter of Intent 20
- 2.7 Material Transfer Agreements 21
- 2.8 Founder Contracts in Technology Transfers 22
- 2.9 The Technology Transfer Agreement Contract Itself 24
- 2.10 Ownership of the Rights 25
- 2.11 Subject Matter of the Contract 26
- 2.12 Domains 26
- 2.13 Territory 27

2.14	Know-How	27
2.15	Financial Considerations	28
2.16	Financial Clauses	29
2.17	Improvements	30
2.18	Rights of First Refusal	32
2.19	Circulation of Contracts	32
2.20	Antistacking Clause	32
2.21	Various Clauses	33
2.22	Conclusions	34
3	Technology Transfer at the National Institutes of Health	35
	<i>Mark L. Rohrbaugh and Brian R. Stanton</i>	
3.1	Introduction	35
3.2	Technology Transfer Legislation	36
3.3	Impact of Bayh–Dole and Stevenson–Wylder Acts	38
3.4	Growth of Technology Transfer in Government and Academic Laboratories	39
3.5	NIH Efforts to Transfer Technology Globally	45
3.6	International Technology Transfer by Publicly Funded Research Organizations	46
3.7	Patent Harmonization and Access to Medicines	55
3.8	Final Notes on the Global Expansion of Bayh–Dole-Type Intellectual Property Regimes	57
4	Current Intellectual Property Management Situation in Japan	59
	<i>Yukiko Nishimura and Katsuya Tamai</i>	
4.1	Introduction	59
4.2	IP-Related Government Measures and Projects	59
4.3	Life Sciences/Biotechnology-Related Projects	63
4.4	Medical Patent/Patentability	65
4.5	Policies related to University–Industry Collaboration Incorporation of National Universities	70
5	Technology Transfer in China	79
	<i>Jiayang Yu</i>	
5.1	Introduction	79
5.2	Overview	79
5.2.1	Technology Import	79
5.2.2	Importing Sources and Industry Dissemination	80
5.2.3	Biotechnology	81
5.2.4	Technology Export	82
5.2.5	Government Policy	82
5.3	Legal Protection of Technology in China	84

5.3.1	Patent Protection	84
5.3.1.1	Patent Filing and Prosecution	84
5.3.1.2	Patent Enforcement	84
5.3.1.3	Patent Enforcement Data	87
5.3.1.4	Strategic Considerations	88
5.3.2	Trade Secret Protection	88
5.3.2.1	Contractual Protection	88
5.3.2.2	Protection under the Anti-Unfair Competition Law	89
5.3.2.3	Criminal Sanctions	89
5.3.2.4	Strategic Considerations	89
5.3.3	Other Forms of Protection	90
5.4	Technology Transfer in China	90
5.4.1	Technology Import and Export	90
5.4.1.1	Contract Law	91
5.4.1.2	Import and Export Regulations	91
5.4.2	Technology Import and Export: Government Regulations	92
5.4.2.1	Three Categories	92
5.4.2.2	Technology Prohibited to Import or Export	92
5.4.2.3	Technology Restricted to Import or Export	92
5.4.2.4	Technology Free to Import or Export	93
5.4.2.5	License and Registration Certificate	94
5.4.2.6	Technology as Investment	94
5.4.2.7	Legal Liabilities and Judicial Review	94
5.4.2.8	Import or Export of Dual-Use Technologies	94
5.4.3	Technology Import and Export: Important Issues	95
5.4.3.1	Definition of Technology Contract	95
5.4.3.2	Forms of Contract	95
5.4.3.3	Content of Contract	95
5.4.3.4	Technology Supplying Party's Obligations	96
5.4.3.5	Confidentiality and Contract Term	96
5.4.3.6	Restrictive Clauses	96
5.4.3.7	Taxation	98
5.4.3.8	Governing Law	98
5.4.3.9	Dispute Resolution	99
5.4.3.10	Statute of Limitations	99
5.5	Conclusions	99
6	Technology Transfer in Latin-America	101
	<i>Claudia Ines Chamas</i>	
6.1	Introduction	101
6.2	Academia, Industry and Technology Transfers	101
6.3	Support Structures for Investments in Biotechnology	106
6.4	Policies for Marketing Biotechnological Knowledge	112
6.5	Conclusions and Final Remarks	119

Part II Perspectives from Different Participants/Players 121**7 Technology Transfer in Agricultural Biotechnology: Impact of Applied Plant Sciences on Industry 123***Marc Cornelissen and Michiel M. van Lookeren Campagne*

- 7.1 Introduction 123
- 7.2 Historical Perspective 124
 - 7.2.1 First-Generation Crops 124
 - 7.2.2 New Innovation Wave 124
 - 7.2.3 Third Innovation Wave 125
- 7.3 Market Development 126
 - 7.3.1 Overwhelming Success 126
 - 7.3.2 Full Potential Not Reached 127
 - 7.3.3 Future Developments 127
- 7.4 Technology Transfer Through Open Innovation Platforms as a Key to Success 128
 - 7.4.1 Introduction 128
 - 7.4.2 Need for Innovative Raw Materials as a Driving Force 128
 - 7.4.3 Intensification of Coordination and Communication 128
 - 7.4.4 Involvement of Society 129
 - 7.4.5 Responsible Industry 130
 - 7.4.6 Common Interests 130
 - 7.4.7 Open Innovations Platforms 131
 - 7.4.8 Coordinator Role in Industry 131
 - 7.4.9 Opportunities for Academia and Start-Ups 132
 - 7.4.10 Key Factor: Technology Transfer 132
- 7.5 Specifics of Technology Transfer in Agricultural Biotechnology and Their Consequences 132
 - 7.5.1 Introduction 132
 - 7.5.2 Transition Points 133
 - 7.5.2.1 Transfer to Agricultural Biotechnology 133
 - 7.5.2.2 Downstream from Agricultural Biotechnology 133
 - 7.5.2.3 To End-Consumers 134
 - 7.5.3 Expression of Traits 135
- 7.6 Technology Transfer and Start-Up Companies in Agricultural Biotechnology 135
 - 7.6.1 Introduction 135
 - 7.6.2 Less-Favorable Prospects 135
 - 7.6.3 Stimulatory Measures 137
- 7.7 Future 137
 - 7.7.1 Introduction 137
 - 7.7.2 Diversification and Specialization 137
 - 7.7.3 Evolution in R&D 138
 - 7.7.4 Shifts in National Budgets 138

- 7.7.5 The ‘Stimulating Government’ 139
- 7.7.6 Self-Sustaining Process 139

8 Technology Transfer Issues in Biotechnology: The Industry Point of View 141

Florent Gros

- 8.1 Introduction 141
- 8.2 Diversity of Legal Frameworks 142
- 8.3 Intellectual Property Dangers 147
- 8.4 Industry Out-Licensing Prospects 148
- 8.5 Industry In-Licensing Practices 150
- 8.6 Challenges Related to Biotechnology 154
- 8.6.1 Experimental-Use Exemptions 154
- 8.6.2 How Essential are Patented Genes? 155
- 8.7 Biodiversity Convention 157
- 8.8 Industry Motivation Driving R&D Investments 158

9 A Quarter Century of Technology Transfer in US Universities and Research Institutions 161

Lita Nelsen

- 9.1 Introduction 161
- 9.2 Enabling Legislation 162
- 9.2.1 Public Purpose of Bayh–Dole 162
- 9.2.2 Returns and Economic Development 163
- 9.2.3 Start-Up Companies and Entrepreneurship 164
- 9.3 Lessons Learned in a Quarter Century of Technology Transfer 165
- 9.3.1 Expectations in Setting Up a Program 166
- 9.3.1.1 Licensing Income 167
- 9.3.1.2 Building a Program Takes Time and Money 167
- 9.3.1.3 Culture Change 167
- 9.3.1.4 Defining the Mission 168
- 9.3.1.5 Setting the Ground Rules: Policies and Practices 168
- 9.3.1.6 Conflicts of Interest 168
- 9.3.1.7 Talent 169
- 9.4 Conclusions 170

10 Technology Transfer Issues in Biotechnology: The Future of Global Health Networks 173

Gerald T. Keusch and Ashley J. Stevens

- 10.1 Introduction 173
- 10.2 Knowledge for All 174
- 10.3 Knowledge Sequestration 175
- 10.4 New Research Models 175

